Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$196.79−10.01 (-4.84%)
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Moderna Employee and contractor work-related fatalities by Year
Employee and contractor work-related fatalities (fatalities)
Moderna Employee and contractor work-related fatalities: 0.00 fatalities in FY2025.
Latest, FY2025
0.00
Period ended Dec 31, 2025
Change on a year earlier
–
0.00 in FY2024
History
3 years
Since FY2023
Sources
1
2025 Impacting Human Health Report
Where the FY2025 figure comes from
“Fatalities(2) 0 0 0”
Source: 2025 Impacting Human Health Report ↗
Reported in Moderna 2025 Impacting Human Health Report.
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Employee and contractor work-related fatalities (fatalities) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.00 | – | 2025 Impacting Human Health Report ↗ |
| FY2024 | Dec 31, 2024 | 0.00 | – | 2025 Impacting Human Health Report ↗ |
| FY2023 | Dec 31, 2023 | 0.00 | – | 2025 Impacting Human Health Report ↗ |
Cite this data
StockData. (2026). Moderna Employee and contractor work-related fatalities, annual FY2023–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ehs-fatalities
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.
See a number that looks wrong?